What is Leerink Partnrs’ Estimate for CTNM Q3 Earnings?

Contineum Therapeutics, Inc. (NASDAQ:CTNM) – Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Contineum Therapeutics in a research note issued on Thursday, September 25th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings of ($0.67) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Contineum Therapeutics’ current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Contineum Therapeutics’ Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.63) EPS, Q1 2026 earnings at ($0.76) EPS, Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.85) EPS and FY2026 earnings at ($2.83) EPS.

Contineum Therapeutics (NASDAQ:CTNM) last released its earnings results on Tuesday, August 5th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06).

CTNM has been the topic of a number of other research reports. Leerink Partners started coverage on shares of Contineum Therapeutics in a research note on Thursday. They set an “outperform” rating and a $20.00 target price on the stock. Morgan Stanley boosted their price target on shares of Contineum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Monday, August 18th. Finally, William Blair initiated coverage on shares of Contineum Therapeutics in a research note on Friday, June 20th. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $22.20.

Contineum Therapeutics Stock Performance

CTNM opened at $11.92 on Monday. Contineum Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $20.24. The firm’s fifty day moving average is $9.04 and its 200 day moving average is $6.19. The stock has a market cap of $334.24 million, a price-to-earnings ratio of -5.42 and a beta of 1.13.

Institutional Trading of Contineum Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Marex Group plc purchased a new stake in Contineum Therapeutics in the 2nd quarter worth $45,000. Bridgeway Capital Management LLC bought a new stake in shares of Contineum Therapeutics in the 2nd quarter worth about $76,000. Jane Street Group LLC bought a new stake in shares of Contineum Therapeutics in the 2nd quarter worth about $81,000. RBF Capital LLC bought a new stake in shares of Contineum Therapeutics in the 2nd quarter worth about $159,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Contineum Therapeutics in the 2nd quarter worth about $43,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).